Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 237-438-9
CAS number: 13784-51-5
Physico-chemical characteristics show the substance is highly water
soluble, and has a low logKow. This is inline with the biological,
including some toxicological effects seen in repeated oral dose study in
rats. Hydrolysis studies showed that at a pH value of 7 the half-life
(t½) for 2,4 -pentanedione peroxide at a temperature of 20°C was
calculated to be 200 hours; at a pH value of 9 the half-life (t½) for
2,4 -pentanedione peroxide at a temperature of 20°C was calculated to be
12.5 hours; and at pH value 4 no reliable results were observed so no
information on hydrolysis can be given.
Specific test data are not available on the toxicokinetics of the test
item. However, the evidence for the absorption/distribution of the test
item is available in rats, mice and rabbits.
In a 28-day repeated oral gavage study with rats, based on
treatment-related microscopic findings of squamous hyperplasia and
hyperkeratosis of forestomach, as well as mucosal necrosis of glandular
stomach in males and females treated with 1000 mg/kg/day a
(NOAEL) of 300 mg/kg body weight/day of 2,4-Pentanedione, peroxide was
established for the rat. Other test item-related (non-adverse and
typically adaptive) microscopic findings noted included hypertrophy of
mucosal epithelium of duodenum, centrilobular hepatocellular hypertrophy
and extramedullary erythrocytic hemopoiesis (i.e. erythropoiesis) in
femur bone marrow, enhanced hyaline droplets in renal proximal tubules,
and tubular basophilia in the kidney. Hematology and clinical
biochemistry parameter changes showed mild aberrations in lipid
These changes support the absorption of the test item from the
gastrointestinal tract of the rat, and the distribution into internal
organs at sufficient concentrations of the test item (or its
metabolites) to cause biological effects in a generally dose-dependent
In NMRI BR mice used in the in vivo micronucleus test, a single
intraperitoneal injection of the test item resulted in dose-dependent
clinical signs of toxicity (ataxia) at 375 to 1500 mg/kg body weight
revealing the absorption and distribution of the test item within the
The sensitization study results from the Himalayan rabbits showed that
the epicutaneously applied test item was effective in eliciting a
positive immune system response on the skin (“strong sensitizer”)
suggesting dermal absorption occurs.
No data are available on the metabolism and elimination from the body,
but the substance is presumed to be metabolized, detoxified and
eliminated in urine (and in feces if oral exposure occurs).
are not available on the toxicokinetics, metabolism and distribution of
the test substance.
peroxide is not commercially available. The test substance as tested was
a ~30% mixture of peroxide containing solvent and stabilizer. Evidence
of absorption and distribution of the test item can be inferred from the
availablein vivo studies in rats (repeated oral gavage), mice
(single intraperitoneal injection), and guinea pigs (single intradermal
injection / epidermal application).
Due to the
low molecular weight, high water solubility and low log Pow values, the
test substance is expected to pass through aqueous pores or be carried
through the epithelial barriers by the bulk passage of water.
In a 28-day
repeated oral gavage study with rats, based on treatment-related
microscopic findings of squamous hyperplasia and hyperkeratosis of
forestomach, as well as mucosal necrosis of glandular stomach in males
and females treated with 1000 mg/kg/day, a
of 300 mg/kg body weight/day of 2,4-Pentanedione, peroxide was
established. Other test item-related (non-adverse and typically
adaptive) microscopic findings noted included hypertrophy of mucosal
epithelium of duodenum, centrilobular hepatocellular hypertrophy,
extramedullary erythrocytic hemopoiesis (i.e. erythropoiesis) in femur
bone marrow, enhanced hyaline droplets in renal proximal tubules, and
tubular basophilia in the kidney. Hematology and clinical biochemistry
parameter changes showed mild aberrations in lipid metabolism.
are considered as the evidence for absorption of the test substance from
the gastrointestinal tract of the rat, and distribution into internal
organs at sufficient concentrations (either the test substance or
metabolites) causing effects at tissue and cellular levels in a
generally dose-dependent manner.
the micronucleus test results were negative in mice after a single
intraperitoneal injection, in preliminary experiments, the absorption,
distribution, and clinical effects of the test substance were implied
from the dose-dependent (375 to 1500 mg/kg body weight) behavioral
changes (e.g., lethargy, ventro-lateral recumbency, and ataxia) seen
within the first 2 hours of dosing the animals.
Based on the physical
properties (molecular weight, and water solubility, low Kow), the test
item is expected to have a some degree of dermal absorption. The
sensitization study concluded that the test substance is a sensitizer in
guinea pigs showing that the test substance is absorbed from the skin in
sufficient concentration to cause a positive immune system effect, which
is a systemic response. However, the
substance is not irritating to skin and increased absorption due to
damaged skin is therefore not very likely. An
acute dermal study showed a high LD50 (>2000 mg/kg). Therefore, dermal
absorption was considered to be 25% for long term systemic DNEL
pressure of the peroxide was 6.28 Pa at 20oC. Inhalation is
not expected to be a major route of exposure. .
substance is biodegradable. No information is available on the
metabolism or elimination of the test substance in animals.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Acest site folosește module cookie pentru a garanta că aveți parte de cea mai bună experiență pe paginile noastre.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again